Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Fisk

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2008
Social anxiety in a multiple sclerosis clinic populationK Poder, K Ghatavi, J D Fisk, et al.
AJR. American Journal of Roentgenology|February 1, 1981
Gastrointestinal radiographic features of human graft-vs.-host diseaseJ D Fisk, H M Shulman, R R Greening, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2009
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluationP J Veugelers, J D Fisk, M G Brown, et al.
International Journal of Technology Assessment in Health Care|October 12, 2000
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimatesM G Brown, T J Murray, I S Sketris, et al.
Chronic Diseases and Injuries in Canada|July 4, 2014
Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova ScotiaR A Marrie, J D Fisk, K J Stadnyk, et al.
European Journal of Neurology|February 5, 2019
Prodrome in relapsing-remitting and primary progressive multiple sclerosisJ M A Wijnands, F Zhu, E Kingwell, et al.
Pain|July 1, 1994
Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patientsC J Archibald, P J McGrath, P G Ritvo, et al.
Neurology|August 20, 2008
How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?Steven R Brenner, M G Brown, S Kirby, et al.
British Journal of Rheumatology|April 1, 1993
Cognitive impairment and autoantibodies in systemic lupus erythematosusJ G Hanly, N M Walsh, J D Fisk, et al.
Multiple Sclerosis and Related Disorders|September 9, 2015
Comorbidity is associated with pain-related activity limitations in multiple sclerosisK M Fiest, J D Fisk, S B Patten, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2008
Social anxiety in a multiple sclerosis clinic populationK Poder, K Ghatavi, J D Fisk, et al.
AJR. American Journal of Roentgenology|February 1, 1981
Gastrointestinal radiographic features of human graft-vs.-host diseaseJ D Fisk, H M Shulman, R R Greening, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2009
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluationP J Veugelers, J D Fisk, M G Brown, et al.
International Journal of Technology Assessment in Health Care|October 12, 2000
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimatesM G Brown, T J Murray, I S Sketris, et al.
Chronic Diseases and Injuries in Canada|July 4, 2014
Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova ScotiaR A Marrie, J D Fisk, K J Stadnyk, et al.
European Journal of Neurology|February 5, 2019
Prodrome in relapsing-remitting and primary progressive multiple sclerosisJ M A Wijnands, F Zhu, E Kingwell, et al.
Pain|July 1, 1994
Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patientsC J Archibald, P J McGrath, P G Ritvo, et al.
Neurology|August 20, 2008
How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?Steven R Brenner, M G Brown, S Kirby, et al.
British Journal of Rheumatology|April 1, 1993
Cognitive impairment and autoantibodies in systemic lupus erythematosusJ G Hanly, N M Walsh, J D Fisk, et al.
Multiple Sclerosis and Related Disorders|September 9, 2015
Comorbidity is associated with pain-related activity limitations in multiple sclerosisK M Fiest, J D Fisk, S B Patten, et al.
Pageof 6